Abiraterone acetate.

Abstract

Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.

• Journal: Drugs in R&D (Drugs R D) Vol. 10 Issue 4 Pg. 261-9 ( 2010) ISSN: 1179-6901 [Electronic] New Zealand
• PMID: 21171672 (Publication Type: Journal Article, Review)

Chemical References

• Androgen Antagonists
• Androstadienes
• Antineoplastic Agents, Hormonal
• Drugs, Investigational
• Prodrugs
• Abiraterone Acetate

Topics

• Abiraterone Acetate
• Androgen Antagonists (pharmacology, therapeutic use)
• Androstadienes (pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents, Hormonal (pharmacology, therapeutic use)
• Drug Evaluation, Preclinical
• Drugs, Investigational (pharmacology, therapeutic use)
• Humans
• Neoplasms (drug therapy)
• Prodrugs (pharmacology, therapeutic use)